Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;144(4):553-561.
doi: 10.1097/AOG.0000000000005712. Epub 2024 Aug 30.

Body Mass Index Changes Among Adolescents and Young Adults Using the Etonogestrel Contraceptive Implant

Hunter J Wernick  1 , Mahmoud Abdel-Rasoul, Elise D Berlan, Andrea E Bonny
Affiliations

Body Mass Index Changes Among Adolescents and Young Adults Using the Etonogestrel Contraceptive Implant

Hunter J Wernick et al. Obstet Gynecol. .

Abstract

Objective: To evaluate body mass index (BMI) over 36 months among adolescents and young adults using the etonogestrel implant compared with those using depot medroxyprogesterone acetate (DMPA) and a control group.

Methods: We conducted a retrospective longitudinal cohort study of postmenarchal adolescents and young adults assigned female at birth. The etonogestrel implant and DMPA groups initiated etonogestrel or DMPA between January 1, 2010, and December 31, 2017. Adolescents and young adults in the control group were prescribed a weight-neutral contraceptive or no contraceptive during the same timeframe. The primary outcome of BMI over time was estimated and compared between study groups with inverse probability of treatment weighting linear mixed-effects modeling. Changes in BMI weight category (underweight or normal weight, overweight, obesity) at 12, 24, and 36 months were also explored.

Results: Among the 20,409 eligible patients, 860 initiated etonogestrel, 1,817 initiated DMPA, and 17,732 made up the control group. Compared with individuals in the control group, those in the etonogestrel group had a significantly higher mean BMI difference at 9 months (+0.5, P <.01); at 36 months, the mean BMI difference was +1.0 ( P <.01). Compared with individuals in the control group, those in the DMPA group had higher mean BMI at 6 months (+0.3, P <.01); at 36 months, the mean BMI difference was +1.3 ( P <.01). Regardless of weight changes, increases in BMI weight categories were rare in all groups.

Conclusion: Adolescent and young adult patients who initiated the etonogestrel implant demonstrated BMI changes like those on DMPA and higher than control patients; however, these differences may not be clinically concerning. This study provides important information that can help in counseling adolescent and young adult patients about expectations when starting and using etonogestrel.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure Elise Berlan reports research funding from Merck and Organon, and she is a Nexplanon Clinical Trainer for Merck and Organon. Her institution also received funding from Organon. She has been a Section Editor and peer reviewer for UpToDate. The other authors did not report any potential conflicts of interest.

References

    1. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008;13(suppl 1):4–12. doi: 10.1080/13625180801942754 - DOI
    1. Adolescents and long-acting reversible contraception: implants and intrauterine devices. ACOG Committee Opinion No. 735. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e130–9. doi: 10.1097/AOG.0000000000002632 - DOI
    1. Szucs LE, Lowry R, Fasula AM, Pampati S, Copen CE, Hussaini KS, et al. Condom and contraceptive use among sexually active high school students—Youth Risk Behavior Survey, United States, 2019. MMWR Suppl 2020;69:11–8. doi: 10.15585/mmwr.su6901a2 - DOI
    1. Swanson KJ, Gossett DR, Fournier M. Pediatricians' beliefs and prescribing patterns of adolescent contraception: a provider survey. J Pediatr Adolesc Gynecol 2013;26:340–5. doi: 10.1016/j.jpag.2013.06.012 - DOI
    1. Pritt NM, Norris AH, Berlan ED. Barriers and facilitators to adolescents' use of long-acting reversible contraceptives. J Pediatr Adolesc Gynecol 2017;30:18–22. doi: 10.1016/j.jpag.2016.07.002 - DOI

MeSH terms

LinkOut - more resources